Market Research Reports, Inc. has announced the addition of “Global Hypertrophic Cardiomyopathy Therapeutics Market 2017 - 2021” research report to their website www.MarketResearchReports.com

Lewes, DE -- (SBWire) -- 04/20/2017 --Report forecast the global hypertrophic cardiomyopathy therapeutics market to grow at a CAGR of 1.80% during the period 2017-2021.

HCM is the enlargement of the heart muscle (myocardium), which disrupts the functions of the heart. HCM is mostly caused due to gene mutation and is a significant cause of sudden cardiac death in any age group. Hypertrophy is defined as an enlargement of a tissue or organ, and cardiomyopathy refers to diseases related to heart muscles. Therefore, HCM is defined as a condition, which is characterized by abnormal thickening of heart muscles, which makes pumping of blood from the heart to various organs difficult. Therefore, the heart must induce more pressure to pump blood to various vital organs.

The report covers the present scenario and the growth prospects of the global hypertrophic cardiomyopathy therapeutics market for 2017-2021. To calculate the market size, the report presents a detailed picture of the market by way of study, synthesis, and summation of data from multiple sources.

The market is divided into the following segments based on geography:
- Americas
- APAC
- EMEA

According to the report, one driver in market is increasing cases of HF. HCM is an extended form of a diastolic HF when the heart fails to perform its functions normally. The diastolic HF occurs when the lower left chamber or the LV is not filled properly with blood during the diastolic phase. Therefore, the amount of pumped blood is less than the normal. Similarly, in HCM, the increasing myocardium size results in smaller LV cavity size accompanied by impairment of blood flow. This leads to the common symptoms of both HCM and HF such as dyspnoea, angina, palpitations, syncope, and presyncope. Hence, the drug development for relieving the symptoms of HF benefits the global HCM therapeutics market as well. As per the CDC, more than five million people are living with HF in the US, and about half of the affected population succumb within five years of diagnosis. However, the deaths due to HF have significantly declined in the past few years due to improved therapies to treat the disease. However, the risk of developing HF continues to rise with the increasing population. This risk-factor has further triggered R&D for newer drugs, which can be repurposed for the diagnosis and treatment of HCM. The traditional HCM drug market has a long history of repurposed drugs for its prevention and cure. There are many drugs belonging to drug classes such as beta-adrenergic blockers, calcium channel blockers, and antiarrhythmic, which were originally developed for the treatment and prevention of HF and are now being employed in the treatment of HCM.

Further, the report states that one challenge in market is expensive serial screenings. Individuals with HCM may be asymptomatic or may complain of mild chest pain; CHF symptoms; or syncope, which is the temporary loss of consciousness due to fall in BP. The morphologic diagnosis is characterized by the presence of hypertrophied myocardium and non-dilated LV in the absence of other cardiac diseases that are capable of causing myocardium hypertrophy of more than 15 mm in an adult patient or equivalent to relative body surface area in children. The serial screening for evaluation of HCM includes two-dimensional echocardiography ($1,500), 24-hour ambulatory (Holter) electrocardiographic monitoring, 12-lead ECG, CMR, and TTE ($2,000) and evaluation by a cardiologist at an experienced center. These tests are not only time consuming but also very expensive and may pose a financial burden on an individual's family, thereby increasing anxiety and stress for the family.

Global Hypertrophic Cardiomyopathy Therapeutics Market 2017-2021, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

key players in the global hypertrophic cardiomyopathy therapeutics market: AstraZeneca, Merck, Pfizer, and Sanofi

Other Prominent Vendors in the market are: Gilead Sciences, Novartis, and Teva Pharmaceutical Industries.

Market driver
- Adoption of sedentary lifestyle.
- For a full, detailed list, view our report

Market challenge
- Technological advances in devices.
- For a full, detailed list, view our report

Market trend
- Development of translational bioinformatics (TBI).
- For a full, detailed list, view our report

Key questions answered in this report
- What will the market size be in 2021 and what will the growth rate be?
- What are the key market trends?
- What is driving this market?
- What are the challenges to market growth?
- Who are the key vendors in this market space?
- What are the market opportunities and threats faced by the key vendors?
- What are the strengths and weaknesses of the key vendors?

Spanning over 70 pages and 43 Exhibits "Global Hypertrophic Cardiomyopathy Therapeutics Market 2017 - 2021" report covers Executive summary, Scope of the report, Market research methodology, Introduction, Market landscape, Disease overview, Key clinical trials, Market dynamics, Market segmentation by drug-class, Geographical segmentation, Decision framework, Drivers and challenges, Market trends, Vendor landscape, Key vendor analysis, Appendix.

For more information Visit at: http://www.marketresearchreports.com/technavio/global-hypertrophic-cardiomyopathy-therapeutics-market-2017-2021

Related Reports;

Global Neurovascular Stents Market 2017-2021 - Visit at - http://www.marketresearchreports.com/technavio/global-neurovascular-stents-market-2017-2021

Global Botulinum Toxin Market 2017-2021 - Visit at - http://www.marketresearchreports.com/technavio/global-botulinum-toxin-market-2017-2021

About Market Research Reports, Inc.
Market Research Reports, Inc. is the world's leading source for market research reports and market data. We provide you with the latest market research reports on global markets, key industries, leading companies, new products and latest industry analysis & trends.

Yearly/Quarterly Report Subscription: http://www.marketresearchreports.com/subscriptions